Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma

Abstract

4p16.3 has previously been identified as a region of non-random LOH in transitional cell carcinoma, suggesting the presence of a tumour suppressor gene. One candidate within this region is fibroblast growth factor receptor 3 (FGFR3). Germline mutations in FGFR3 are known to cause several autosomal dominant skeletal dysplasias, the severity of which depends on the position and nature of the mutation in the protein. We investigated the frequency and nature of FGFR3 mutations in a panel of transitional cell carcinomas and cell lines and studied the possible link between mutation and loss of heterozygosity (LOH) on 4p16.3. FGFR3 coding sequence from 63 transitional cell carcinomas (TCC) of various stages and grades, and 18 cell lines was analysed by fluorescent SSCP. Samples with abnormal migration patterns were sequenced to identify the mutation or polymorphism. Thirty-one of the 63 tumours had previously been assessed to have LOH at 4p16.3. Twenty-six of the 63 tumours (41%) and 4/18 (22%) of the cell lines had missense mutations in FGFR3. All mutations detected in our panel have been reported in the germline where all apart from one cause lethal conditions. One tumour contained K652Q which has recently been identified in less severe cases of skeletal dysplasia. Tumours with and without LOH at 4p16.3 had mutations in FGFR3 suggesting that these two events are not causally linked. The frequency of FGFR3 mutation indicates that this protein plays an important role in TCC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Antonarakis SE. . 1998 Hum. Mutat. 11: 1–3.

  • Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ and Francomano CA. . 2000 Am. J. Hum. Genet. (In press).

  • Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H and Donner J. . 1973 Int. J. Cancer 11: 765–773.

  • Buetow KH, Murray JC, Israel JL, London WT, Smith M, Kew M, Blanquet V, Brechot C, Redeker A and Govindarajah S. . 1989 Proc. Natl. Acad. Sci. USA 86: 8852–8856.

  • Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP and Radvanyi F. . 1999 Nat. Genet. 23: 18–20.

  • Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, de Kraker J, Voute PA, Vergnaud G, Westerveld A, Slater R and Versteeg R. . 1996 Hum. Genet. 97: 834–837.

  • Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A and Pierce GF. . 1999 Int. J. Cancer 81: 451–458.

  • Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM and Bergsagel PL. . 1997 Nat. Genet. 16: 260–264.

  • Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM and Bergsagel PL. . 1998 Blood 92: 3025–3034.

  • Elder PA, Bell SM and Knowles MA. . 1994 Oncogene 9: 3433–3436.

  • Elliott AY, Cleveland P, Cervenka J, Castro AE, Stein N, Hakala TR and Fraley EE. . 1974 J. Natl. Cancer Inst. 53: 1341–1349.

  • Forough R, Xi Z, MacPhee M, Friedman S, Engleka KA, Sayers T, Wiltrout RH and Maciag T. . 1993 J. Biol. Chem. 268: 2960–2968.

  • Gey GO, Coffman WO and Kubicek MT. . 1952 Cancer Res. 12: 264–265.

  • Grossman HB, Wedemeyer G, Ren L, Wilson GN and Cox B. . 1986 J. Urol. 136: 953–959.

  • Hadano S, Ishida Y and Ikeda JE. . 1998 DNA Res. 5: 177–186.

  • Hastings RJ and Franks LM. . 1981 Int. J. Cancer 27: 15–21.

  • HMSO. 1994 Cancer registration statistics. England and Wales.

  • Jouanneau J, Plouet J, Moens G and Thiery JP. . 1997 Oncogene 14: 671–676.

  • Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG. . 1994 Cancer Res. 54: 531–538.

  • Kyriazis AA, Kyriazis AP, McCombs WB and Peterson Jr WD. . 1984 Cancer Res. 44: 3997–4005.

  • Landis SH, Murray T, Bolden S and Wingo PA. . 1999 CA Cancer J. Clin. 49: 8–31.

  • Li C, Chen L, Iwata T, Kitagawa M, Fu XY and Deng CX. . 1999 Hum. Mol. Genet. 8: 35–44.

  • Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC and Johnston CL. . 1999 Oncogene 18: 1053–1060.

  • McCombie WR, Martin-Gallardo A, Gocayne JD, FitzGerald M, Dubnick M, Kelley JM, Castilla L, Liu LI, Wallace S, Trapp S et al. 1992 Nat. Genet. 1: 348–353.

  • Mostofi FK, Sobin LH and Humberto T. . 1973 Histological Typing of Urinary Bladder Tumors. WHO, Geneva.

    Google Scholar 

  • Nawroz H, van der Riet P, Hruban RH, Koch W, Ruppert JM and Sidransky D. . 1994 Cancer Res. 54: 1152–1155.

  • O'Toole C, Nayak S, Price Z, Gilbert WH and Waisman J. . 1976 Int. J. Cancer 17: 707–714.

  • O'Toole C, Price ZH, Ohnuki Y and Unsgaard B. . 1978 Br. J. Cancer 38: 64–76.

  • Onose H, Emoto N, Sugihara H, Shimizu K and Wakabayashi I. . 1999 Eur. J. Endocrinol. 140: 169–173.

  • Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG and Kitoh H. . 1999 Hum. Mutat. 14: 115–125.

  • Pauli BU, Cohen SM and Weinstein RS. . 1983 J. Urol. 129: 646–652.

  • Perez-Castro AV, Wilson J and Altherr MR. . 1997 Genomics 41: 10–16.

  • Plowright EE, Li Z, Bergsagel PL, Chesi M, Barber DL, Branch DR, Hawley RG and Stewart AK. . 2000 Blood 95: 992–998.

  • Polascik TJ, Cairns P, Chang WY, Schoenberg MP and Sidransky D. . 1995 Cancer Res. 55: 5396–5399.

  • Pribill I, Barnes GT, Chen J, Church D, Buckler A, Baxendale S, Bates GP, Lehrach H, Gusella MJ, Duyao MP, Ambrose CM, Gusella JF and MacDonald ME. . 1997 Somat. Cell. Mol. Genet. 23: 413–427.

  • Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA and Arnstein P. . 1977 J. Natl. Cancer Inst. 58: 881–890.

  • Richelda R, Ronchetti D, Baldini L, Cro L, Viggiano L, Marzella R, Rocchi M, Otsuki T, Lombardi I, Maiolo AT and Neri A. . 1997 Blood 90: 4062–4070.

  • Rigby CC and Franks LM. . 1970 Br. J. Cancer 24: 746–754.

  • Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Della Porta G and Barbacid M. . 1984 Science 223: 661–664.

  • Sato T, Saito H, Morita R, Koi S, Lee JH and Nakamura Y. . 1991 Cancer Res. 51: 5118–5122.

  • Shivapurkar N, Sood S, Wistuba II, Virmani AK, Maitra A, Milchgrub S, Minna JD and Gazdar AF. . 1999 Cancer Res. 59: 3576–3580.

  • Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA and Fu XY. . 1997 Nature 386: 288–292.

  • Tartaglia M, Saulle E, Bordoni V and Battaglia PA. . 1998 Mol. Cell Probes 12: 335–337.

  • UICC. 1978 Classification of Malignant Tumors, Bladder, edition 3. International Union Against Cancer: Geneva.

  • Vilien M, Christensen B, Wolf H, Rasmussen F, Hou-Jensen C and Povlsen CO. . 1983 Eur. J. Cancer. Clin. Oncol. 19: 775–789.

  • Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y and White R. . 1989 Science 244: 207–211.

  • Webster MK and Donoghue DJ. . 1996 EMBO J. 15: 520–527.

  • Webster MK and Donoghue DJ. . 1997 Mol. Cell. Biol. 17: 5739–5747.

  • Williams RD. . 1980 Invest. Urol. 17: 359–363.

  • Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA and Powell SM. . 1999 Cancer Res. 59: 1437–1441.

  • Zuo J, Robbins C, Taillon-Miller P, Cox DR and Myers RM. . 1992 Hum. Mol. Genet. 1: 149–159.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sibley, K., Cuthbert-Heavens, D. & Knowles, M. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 20, 686–691 (2001). https://doi.org/10.1038/sj.onc.1204110

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204110

Keywords

This article is cited by

Search

Quick links